Literature DB >> 12724623

Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1.

Douglas H Osato1, Conrad C Huang, Michiko Kawamoto, Susan J Johns, Doug Stryke, Joanne Wang, Thomas E Ferrin, Ira Herskowitz, Kathleen M Giacomini.   

Abstract

The human equilibrative nucleoside transporter, ENT1, appears to play a critical role in the disposition of nucleosides and nucleoside analogs used clinically as anti-viral and anti-cancer drugs. Recently, we identified variants of ENT1 in an ethnically diverse DNA sample set from 247 individuals, focusing primarily on the coding region. The goal of the present study was to analyse the haplotype structure and functionally characterize the variants of ENT1. We observed that a single haplotype, ENT1*1, accounted for 91.3% of the 494 chromosomes. Functional analysis in Saccharomyces cerevisiae revealed no differences in the kinetics of uptake of nucleosides and nucleoside analogs by the two non-synonymous variant transporters, ENT1-I216T and ENT1-E391K, and the reference ENT1. These results, together with the observation that there are few haplotypes of ENT1, indicate that coding region variants of ENT1 do not contribute to inter-individual differences in response to nucleoside analog drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12724623     DOI: 10.1097/00008571-200305000-00010

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  21 in total

Review 1.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

2.  Functional genomics of membrane transporters in human populations.

Authors:  Thomas J Urban; Ronnie Sebro; Evan H Hurowitz; Maya K Leabman; Ilaria Badagnani; Leah L Lagpacan; Neil Risch; Kathleen M Giacomini
Journal:  Genome Res       Date:  2005-12-14       Impact factor: 9.043

Review 3.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

Review 4.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

Review 5.  Pharmacogenetics and pharmacoepigenetics of gemcitabine.

Authors:  M Candelaria; E de la Cruz-Hernández; E Pérez-Cárdenas; C Trejo-Becerril; O Gutiérrez-Hernández; A Dueñas-González
Journal:  Med Oncol       Date:  2009-11-10       Impact factor: 3.064

6.  Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.

Authors:  Taro Okazaki; Milind Javle; Motofumi Tanaka; James L Abbruzzese; Donghui Li
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

Review 7.  Equilibrative nucleoside transporters-A review.

Authors:  Rebba C Boswell-Casteel; Franklin A Hays
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2016-10-19       Impact factor: 1.381

Review 8.  Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

Authors:  Raphaël Maréchal; Anne Demols; Jean-Luc Van Laethem
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

9.  Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization.

Authors:  Geoff Daniels; Bryan A Ballif; Virginie Helias; Carole Saison; Shane Grimsley; Lucienne Mannessier; Hein Hustinx; Edmond Lee; Jean-Pierre Cartron; Thierry Peyrard; Lionel Arnaud
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

Review 10.  Genetic factors influencing cytarabine therapy.

Authors:  Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.